The goal of this study was to determine whether protein kinase C mediates bradykinin-induced increases in microvascular permeability. Permeability of the hamster cheek pouch was evaluated using intravital fluorescent microscopy and fluorescein isothiocyanate (FITC)dextran (MW 70,000). We examined effects of sphingosine, a protein kinase C inhibitor, on bradykinin-induced increases in permeability. Increases in permeability were quantitated by counting the number of leaky sites and calculating the clearance of FITC-dextran. During bradykinin (10-6 M), leaky sites increased from 0 to 40±4 (mean+SEM) sites/0.11 cm2, and clearance increased from 1.7±+1.0 to 22±9 ml/secxlO-6. The bradykinin type-2 receptor antagonist D-Arg, [Hyp3,Thi5,8,D-Phe7] -bradykinin virtually abolished formation of leaky sites in response to bradykinin. To determine whether changes in microvascular pressure contribute to the increase in leaky sites, venular pressure was measured using a micropipette and survo-null device. Increases in cheek pouch venular pressure were similar during application of bradykinin and adenosine, which increased permeability, and isoproterenol, which did not increase permeability in the cheek pouch. Thus, increases in permeability were not linked to From the
changes in microvascular pressure. The protein kinase C inhibitor, sphingosine (10-6 M), markedly attenuated responses to bradykinin. Leaky sites increased from 0 to only 2±1 sites/0.11 cm2, and clearance increased from 3.9±1.4 to only 6.7+2.2 ml/secx 10-6. To test the specificity of sphingosine, we examined effects of adenosine (10-6 M). Sphingosine did not significantly alter increases in microvascular permeability in responses to adenosine. We also examined effects of 1-(5-isoquinolinylsulfonyl)-2-methylpiperazine (H-7), another protein kinase C inhibitor, on responses to bradykinin and adenosine. H-7 greatly attenuated formation of leaky sites during stimulation with bradykinin and did not alter the number of leaky sites produced during adenosine. The findings suggest that protein kinase C may mediate increases in vascular permeability in response to bradykinin. (Circulation Research 1991;68:1340-1348) B radykinin and related kinins increase vascular permeability.' Morphological evidence suggests that bradykinin increases macromolecular efflux through the formation of intercellular gaps between endothelial cells23 that are located principally in postcapillary venules. 4 Responses to kinins are mediated by activation of specific bradykinin receptors. 5, 6 In cultured endothelial cells, bradykinin activates protein kinase C through the formation of diacylglycerol, a product of phospholipase C hydrolysis of phosphatidylinositol.7-13 Protein kinase C may be a mediator of pulmonary edema, since the activation of this enzyme with phorbol myristate acetate14-18 or H2O219 produces increases in vascular permeability and/or capillary pressure in isolated lungs and whole animals. This finding implicates protein kinase C as a possible mediator of increases in vascular permeability.
In previous studies, exogenous agonists (usually phorbol esters)14-18 or H20219 were used to activate protein kinase C in vivo. There have been no studies, to our knowledge, that have tested the hypothesis that endogenous stimuli increase vascular permeability by activation of protein kinase C. The goal of this study was to determine the role of protein kinase C in bradykinin-induced increases in permeability of the microcirculation in vivo. We used two antagonists, sphingosine and 1-(5-isoquinolinylsulfonyl)-2-methylpiperazine (H-7), that inhibit protein kinase C through different mechanisms. Sphingosine inhibits activation of protein kinase C by competing with diacylglycerol for binding to the regulatory site.2021 In contrast, H-7 apparently inhibits protein kinase C by competing with ATP for binding to the catalytic site on protein kinase C.22,23 These inhibitors were used to elucidate a possible role of protein kinase C in microvascular responses.
Materials and Methods Agents
Bradykinin, H-7, adenosine, D-Arg,[Hyp3,Thi5 8,D-Phe71-bradykinin, and des-Arg9-bradykinin were purchased from Sigma Chemical Co., St. Louis.
Preparation ofAnimals
Adult, male Syrian hamsters weighing 130-180 g were anesthetized with sodium pentobarbital (6 mg/ 100 g body wt, i.p.) and tracheotomized to facilitate spontaneous respiration. A femoral artery was cannulated to obtain blood samples. A femoral vein was cannulated for injection of the intravascular tracer fluorescein isothiocyanate (FITC)-dextran (MW 70,000, 50 mg/100 g body wt) and for injection of supplemental anesthesia (3 mg/100 g body wt/hr).
The left cheek pouch was prepared for intravital fluorescent microscopy and sampling of suffusate, using a technique similar to that described previously. 24 Briefly, the cheek pouch was spread gently over a small plastic baseplate, and an incision was made in the outer skin to expose the cheek pouch membrane. A thick, vascular layer of connective tissue was carefully incised and removed to expose the microvasculature of the cheek pouch. The upper chamber was positioned over the baseplate and secured in place by suturing the skin around the upper chamber with a purse-string technique. The arrangement forms a triple-layered complex: the baseplate, upper chamber, and the cheek pouch membrane exposed between these two plates. 24 The hamster was then placed on a Lucite board positioned on a heating mat regulated at 37°C. The chamber was connected to a reservoir containing a bicarbonated buffer, which was continuously bubbled with 95% N2-5% CO2. Throughout the experiment, the pouch was suffused with buffer, and the temperature in the chamber was maintained constant at 37°C. The chamber was also connected via a threeway valve to an infusion pump (Sage Instruments, Cambridge, Mass.) for administration of drugs into the suffusate.
The cheek pouch vasculature was epi-illuminated with a vertical illuminator and viewed through an Olympus microscope (Jewelmont Microscope, Minneapolis, Minn.). Fluorescent microscopy was accomplished with filters that matched the spectral characteristics of FITC-dextran. Diameter of blood vessels was measured by recording the image on videotape and later measuring the diameter with an imageshearing device (model 908, Instrumentation for Physiology & Medicine, Inc., San Diego).
Leukocyte rolling and adhesion in postcapillary venules in the hamster cheek pouch has been reported previously during superfusion with leukotriene B4.25 In our studies, leukocyte rolling, or adhesion of cells to blood vessels, was not observed.
Measurements of Perneability
Macromolecular leakage is manifested by extravasation of FITC-dextran, which appeared as fluorescent spots or "leaky sites," as described previously. 24 After the administration of a drug, the number of leaky sites was determined by visually counting three random fields. The location and number of leaky sites in each field (0.11 cm2) were observed after each intervention. To test the accuracy of counting leaky sites, we compared the number of leaky sites counted by two different examiners in several studies (n = 12). The difference in number of leaky sites between the two observers varied by less than 1.5%.
In experiments in which clearance of FITC-dextran was calculated, the suffusion fluid was collected at 5-minute intervals throughout the experiment, using a fraction collector (Micro-fractionator, Gilson Medical Electronics, Inc., Middleton, Wis.). Samples were collected in glass test tubes, and the concentration of FITC-dextran (in nanograms per milliliter) was determined. Arterial blood samples were collected in heparinized capillary tubes (70-,l volume, Scientific Products, McGaw Park, Ill.), beginning 5 minutes before and after injection of FITC-dextran and all successive experimental procedures. During the course of an experiment, < 1 ml blood was obtained through arterial sampling. The mean arterial pressure (105+2 mm Hg at the beginning of an experiment and 90+2 mm Hg at the end) of the hamsters in which arterial samples were obtained was not significantly different from the hamsters in which arterial samples were not obtained (109+2 mm Hg at the beginning of the experiment and 93 ±3 at the end, p>0.05).
To quantitate the concentration of FITC-dextran in the plasma and suffusate, a standard curve for FITC concentration versus percentage transmission was completed on a fluorescence spectrophotometer (The Perkin-Elmer Corp., Norwalk, Conn.). The standard was FITC-dextran (MW 70,000), which was prepared on a weight per volume basis. Bicarbonated buffer was used as a background, and a standard curve was generated for each experiment, which was subjected to linear regression analysis. The percentage transmission for experimental samples (plasma and suffusate) was measured on the spectrophotofluorometer, and the concentration was calculated from the standard curve. It has been shown previously that neutral FITC-dextran does not bind to plasma proteins. 26 Thus, the standard curve was appropriate for analysis of the plasma and suffusate samples. In addition, minimal fluorescence signal (<2% above background) was detected when plasma and suffusate samples were examined before the addition of FITC-dextran.
Clearance of FITC-dextran was determined by calculating the suffusate/plasma concentration of FITCdextran ratio and multiplying by the suffusate flow rate.
Effect of Bradykinin
The dose-response relation for bradykinin was studied. After injection of the FITC-dextran, different dilutions of bradykinin were randomly administered into the suffusate for 5 minutes at final concentrations of 10-', 3 x 10-, 10-6, 3 x 106, and 10-5 M. Leaky sites were determined at 1, 3, 5, 15, and 30 minutes after starting the suffusion of bradykinin. The time interval between each subsequent application of bradykinin was at least 30 minutes. It has been shown previously that intermittent stimulation with bradykinin produced a reproducible response that is not reduced when applied at 30minute intervals. 27 In 14 experiments, we examined effects of sphingosine on responses to bradykinin. Bradykinin (10`6 M) was administered into the suffusate for 5 minutes, and leaky sites were counted. After stimulation with bradykinin, the number of leaky sites returned to control within 45 minutes. Sphingosine (10`6 M) was suffused over the pouch for 10 minutes; bradykinin was again suffused for 5 minutes, and leaky sites were determined. In six of these experiments, the suffusion fluid was collected at 5-minute intervals for the entire experiment. These samples were used to determine the concentration of FITC-dextran in the suffusate (in nanograms per milliliter) before, during, and after application of bradykinin, in the absence and presence of sphingosine.
In two experiments, we examined effects of dimethyl sulfoxide, the vehicle for sphingosine and H-7, on the response to bradykinin (10o-M). Dimethyl sulfoxide (0.1% by volume) was suffused over the pouch for 10 minutes, followed by stimulation with bradykinin for 5 minutes. Suffusion of the pouch with dimethyl sulfoxide did not produce leaky sites and did not reduce the number of leaky sites produced by bradykinin.
In seven other experiments, we studied effects of H-7, another inhibitor of protein kinase C. Bradykinin (10`6 M) was administered into the suffusate for 5 minutes. After at least 45 minutes, H-7 was suffused over the pouch for 10 minutes, followed by stimulation with bradykinin for 5 minutes. The number of leaky sites formed in response to bradykinin was determined in the presence and absence of H-7.
Effect ofAdenosine
To test the specificity of sphingosine and H-7 as inhibitors of bradykinin-induced increases in permeability, we examined their effects on adenosineinduced increases in vascular permeability. Adenosine, as well as bradykinin, produces microvascular leaky sites in the hamster cheek pouch at postcapillary venules. 28 The dose-response relation for adenosine was studied. The number of leaky sites was determined after administration of adenosine into the suffusate at final concentrations of 10'7, 3 x 10-7, 10-6 3 x 10-6, and 10-5 M, given in random order.
In six experiments, we examined the effects of sphingosine (10-6 M) on the response to adenosine (10-6 M). Adenosine was superfused in the absence and presence of sphingosine, and leaky sites were determined.
In six experiments, the suffusion fluid was collected at 5-minute intervals for the entire experiment. These samples were used to determine the concentration of FITC-dextran in the suffusate (in nanograms per milliliter) before, during, and after application of adenosine, in both the absence and presence of sphingosine (10-6 M).
In five experiments, we examined the effect of H-7 on responses to adenosine. Adenosine (10-6 M) was administered into the suffusate for 5 minutes; after at least 45 minutes, H-7 was applied to the pouch for 10 minutes, and the pouch was restimulated with adenosine for 5 minutes. The number of leaky sites formed in response to adenosine was determined in the absence and presence of H-7.
Microvascular Pressure
In six experiments, the pressure in cheek pouch venules was measured with a micropipette connected to a servo-null pressure measuring device (model 4A, Instrumentation for Physiology & Medicine). Pipettes were sharpened to a beveled tip 2-4 ,um in diameter, filled with 1.5 M sodium chloride, and then inserted into the lumen of cheek pouch venules (24-45 ,um in diameter) using a micromanipulator (model MM-33, Brinkmann Instruments, Inc., Westbury, N.Y.). Insertion of the micropipette did not cause bleeding or spasm of venules. Microvascular pressure was measured, and leaky sites were counted during control conditions (superfusion of bicarbonated buffer alone) and during superfusion of either bradykinin (10-6 M), adenosine (10-6 M), or isoproterenol (10-6 M) for 5 minutes.
Characterization of Bradykinin Receptors
In six experiments, we examined the effect of a bradykinin B2 receptor antagonist, D-Arg,[Hyp3, Thi5'8,D-Phe7]-bradykinin, on responses to bradykinin. Bradykinin (10-6 M) was suffused for 5 minutes, and leaky sites were counted. After at least 30 minutes, the B2-receptor antagonist (10-8 and 10M
) was applied to the pouch for 10 minutes, followed by restimulation with bradykinin for 5 minutes, and leaky sites were determined.
To test the specificity of the B2-antagonist, we examined its effect on adenosine-induced increases in permeability. The number of leaky sites was determined before and after administration of adeno- Values for leaky sites are mean ± SEM; n = number of hamsters. There were no leaky sites under baseline conditions. The number of leaky sites after suffusion of bradykinin for 5 minutes is reported. sine (10-6 M) in the absence and presence of the B2-antagonist (10-7 M).
We also examined the effect of a bradykinin B1 receptor agonist, des-Arg9-bradykinin, on the formation of leaky sites in the cheek pouch. In six experiments, des-Arg9-bradykinin (10-6 M) was applied to the pouch for 5 minutes. The number of leaky sites and the diameter of a cheek pouch arteriole and venule (n=4) were determined before and after application of the B1-receptor agonist.
Analysis of Data
Statistical analysis was performed using paired t tests to compare absolute changes in leaky sites, clearance, and vessel diameter during control conditions and experimental interventions. A value of p<0.05 was considered to be significant. Results are expressed as mean+SEM.
Results

Effects of Bradykinin
Under control conditions, there were no leaky sites in the cheek pouch. Application of bradykinin produced leaky sites, which began to appear after 2 minutes and reached a maximum by 5 minutes. Bradykinin increased microvascular permeability in a dose-dependent manner ( Table 1 ). The dose of 1 x 10`6 M bradykinin was chosen for all subsequent experiments.
Effects of Sphingosine
Sphingosine greatly attenuated formation of leaky sites in response to bradykinin (Figure 1 ). In all experiments, bradykinin was reapplied after sphingosine had been washed out of the cheek pouch. After recovery from sphingosine, bradykinin increased leaky sites from 0±0 to 40±9 sites/0.11 cm2, which was similar to the initial response, in which bradykinin increased leaky sites from 0±0 to 40±4 sites/0. 1 cm2. Thus, reduction of bradykinin-induced increases in leaky sites after sphingosine was not due to tachyphylaxis to bradykinin.
Clearance of FITC-dextran remained nearly constant during a 30-45-minute period after stabilization of the preparation. Bradykinin increased clearance of FITC-dextran, and the response was blocked by sphingosine ( Figure 2 ).
Adenosine produced leaky sites, with peak formation occurring at 5 minutes. Adenosine increased microvascular permeability in a dose-dependent manner ( Table 2 ). The dose of 1 x 10`6 M adenosine was chosen for all subsequent experiments, because this dose was not supramaximal. There were no leaky sites under baseline conditions. The number of leaky sites after suffusion of adenosine for 5 minutes is reported.
Sphingosine did not produce leaky sites and did not significantly attenuate adenosine-induced formation of leaky sites (Figure 3 ) or clearance of FITCdextran (MW 70,000) ( Figure 4 ).
Effects of H-7
Application of H-7 did not produce leaky sites. H-7 attenuated the number of leaky sites produced by bradykinin ( Figure 5 ). Reapplication of bradykinin 45-60 minutes after H-7 again increased leaky sites, from 0±0 to 54±10 sites/0.1 1 cm2. Thus, inhibition of leaky site formation after H-7 was not due to tachyphylaxis to bradykinin. H-7 did not attenuate the formation of leaky sites in response to adenosine ( Figure 6 ). 
Microvascular Pressure and Vessel Diameter
Microvascular pressure increased during superfusion of bradykinin, adenosine, and isoproterenol ( Table 3 ). Arteriolar diameter generally increased, and venular diameter was not significantly altered. Superfusion of bradykinin and adenosine, but not isoproterenol, produced leaky sites.
Bradykinin Receptor Antagonists
The B2-receptor antagonist D-Arg,[Hyp3,Thi5'8,D-Phe7]-bradykinin2930 significantly attenuated formation of leaky sites in response to bradykinin ( Figure  7) . Reduction of bradykinin-induced increases in leaky sites after the B2-receptor antagonist was not due to tachyphylaxis, because the time interval between each subsequent application of bradykinin was at least 30 minutes27 and because we were able to demonstrate, in experiments examining effects of sphingosine, that the number of bradykinin-induced leaky sites was virtually identical after the first and third applications of bradykinin (see above).
The B2-antagonist (10-7 M) did not significantly attenuate adenosine-induced formation of leaky sites. The number of leaky sites in response to adenosine was 23±3 versus 22±2 sites/0.11 cm2 in response to adenosine in the presence of the antagonist (n=4,p>0.05). The B1-receptor agonist des-Arg9-bradykinin5 did not cause the formation of leaky sites (0+0 sites/0.11 cm2 before and after des-Arg9-bradykinin). The B1receptor agonist produced significant constriction of arterioles in the cheek pouch (61 ± 13 gm before versus 31±4.4 ,um after application of des-Arg9bradykinin, p<0.05).
Discussion
These results suggest a biochemical mechanism by which bradykinin increases microvascular permeability. The major new finding of this study is that protein kinase C appears to play an essential role in bradykinininduced increases in microvascular permeability in the hamster cheek pouch. This is the first evidence, to our knowledge, that changes in vascular permeability in vivo to an inflammatory stimulus are mediated by protein kinase C. The findings also suggest that adenosine-induced increases in permeability are independent of activation of protein kinase C.
Consideration of Methods
The chamber technique in the hamster cheek pouch enables measurement of solute efflux,24 thereby providing a quantitative appraisal of macromolecular transport. This technique allows permeability to be quantitated in two ways. First, the number of leaky sites can be counted. Second, clearance of FITC-dextran can be quantitated by measuring suffusate concentration of FITC-dextran. It has been shown previously that the number of leaky sites is directly related to clearance of dextran. 24 In this study, we used both leaky site formation and clearance as indicators of microvascular permeability.
As reported previously,24 clearance of dextran is detectable even when there are no observable leaky sites. This "nonspecific" clearance of dextran in the absence of leaky sites may explain in part the finding that, during the recovery period after stimulation with bradykinin or adenosine, leaky sites disappeared but clearance values were somewhat higher than control values. In addition, some dextran may remain in the interstitial space during the recovery period after an increase in permeability, and slow clearance from the interstitial space may increase the concentration of dextran in the suffusate.
In studies of effects of sphingosine, leaky sites and clearance of dextran were used to quantitate increases in permeability. We examined leaky site formation, but not clearance, when examining effects of a second protein kinase C inhibitor, H-7, because the correlation between number of leaky sites and clearance is good during increases in permeability. 24 
Mechanisms ofAction
As demonstrated previously,3,4,31 venules are the site at which bradykinin increases vascular permeability. Classic studies of Majno et al2'32'33 demonstrated that contraction of endothelial cells resulted in the formation of large junctional gaps between adjacent endothelial cells, exclusively in postcapillary venules. Endothelial cells contain contractile pro-teins34-36 and have receptors for a variety of agents, including inflammatory mediators, which provide a mechanism for receptor-activated contraction and relaxation of endothelial cells. Thus, gap formation Thi5",D-Phe7]-bradykinin on leaky sites produced by 10`6 M bradykinin (BK) . Under control conditions (CONT), there were no leaky sites. Values are mean +SEM in six hamsters. *p <0.05 vs. BK between adjacent vascular endothelial cells may be the result of endothelial receptors linked to contractile proteins.
We examined the possibility that the increase in permeability during bradykinin and adenosine was mediated in part by dilatation of precapillary resistance vessels. Bradykinin, adenosine, and isoproterenol all produced arteriolar dilatation, but only bradykinin and adenosine increased permeability. Studies in other tissues and preparations have in general also dissociated vasodilatation from macromolecular leakage. In the rat cremaster muscle, histamine and nitroprusside produced vasodilation and protein leakage, but isoproterenol produced vasodilation without an increase in permeability.37 In the hamster cheek pouch, isoproterenol inhibits increases in permeability induced by bradykinin.4 These studies suggest that vasodilatation produced by stimulation of ,3-adrenergic receptors does not produce an increase in vascular permeability.
None of the vasodilators tested in this study produced venular dilation. Bradykinin, adenosine, and isoproterenol produced similar small increases in venular pressure, but only bradykinin and adenosine increased permeability. These findings suggest that increases in permeability produced by bradykinin and adenosine are not the result of increases in hydrostatic pressure.
We examined receptor mechanisms by which bradykinin increases permeability. B2-receptors exhibit much higher affinity for bradykinin than des-Arg9-bradykinin, whereas B1-receptors are more sensitive to the des-Arg9 metabolites.5 The relative potencies of bradykinin and des-Arg9-bradykinin are often used to classify responses as B2 or B1, respectively. Bradykinin increases vascular permeability, and it has been suggested that this response is mediated via activation of a B2-receptor.5 Our results, using a B2-receptor antagonist,29,30 are in agreement with previous studies and indicate that the B2-receptor mediates the increase in permeability in the cheek pouch in response to bradykinin.
Application of the B1-receptor agonist des-Arg9bradykinin did not increase permeability but did produce significant constriction of arterioles. Constriction of the cheek pouch arterioles indicated that B1-receptors are present in cheek pouch vasculature, because B1-receptors have been reported to produce vasoconstriction. 38 We considered the possibility that inhibition of permeability by sphingosine and H-7 may be related to nonspecific effects on vascular permeability. Adenosine, which increases permeability in the hamster cheek pouch,28 was used to test the specificity of the protein kinase C inhibitors. Adenosine was chosen because, like bradykinin, its effects are receptor mediated. 39 Specific pathways by which adenosine increases permeability have not been clearly established. In the presence of the inhibitors, responses to adenosine were preserved, which suggests that the inhibitors were specific in blocking the effects of bradykinin.
Other studies suggest that, at some concentrations, sphingosine is relatively selective in inhibiting several processes that appear to be mediated by protein kinase C activation. In platelets, sphingosine does not inhibit several other enzymes involved in signal transduction, including phospholipase C, calcium/calmodulin-dependent kinase, diacylglycerol kinase, and cAMP-and cGMP-dependent kinases.20,21 Sphingosine can inhibit calcium/calmodulin-dependent kinases, but the concentrations of sphingosine needed to inhibit calcium/calmodulin-dependent kinases are much higher than the concentration of sphingosine used in this study. 40 The results that we obtained with H-7, which also is an inhibitor of protein kinase C, were similar to those with sphingosine. H-7 inhibits protein kinases, such as cAMP-and cGMP-dependent kinases, as well as myosin light chain kinase.22 However, the concentrations of H-7 necessary to inhibit these kinases are much higher than the concentrations used in this study. 22 The similar findings with the two protein kinase C inhibitors and the concentrations that were efficacious in blocking responses to bradykinin suggest that protein kinase C activity was inhibited relatively selectively.
There was a large difference in concentration of H-7 (10`°M) and sphingosine (10-6 M) that was necessary to block effects of bradykinin, but not adenosine. This difference in potency may be explained by the different sites of action of the inhibitors (Figure 8 ). Sphingosine interacts with the regu-latory domain of protein kinase C,20,21 whereas H-7 interacts at the catalytic domain.22,23 The effective concentration of H-7 was far less than would be expected if H-7 were a receptor antagonist. The potency of H-7 may be explained by its site of action, since H-7 competes with ATP for binding to the catalytic site of protein kinase C. We speculate that the concentration of ATP in endothelial cells of postcapillary venules may be very low, so that a high concentration of H-7 is not necessary for effective inhibition.
In summary, these experiments are the first attempt to determine the biochemical pathway of bradykinin-stimulated increases in permeability in vivo. The main conclusion is that protein kinase C is an integral part of the mechanism by which bradykinin increases microvascular permeability. This conclusion is supported by the observations that sphingosine, which blocks the activation of protein kinase C, and H-7, which blocks the catalytic site on activated protein kinase C, greatly attenuate both formation of microvascular leaky sites and clearance of FITC-dextran (MW 70,000) in response to bradykinin stimulation. This finding, together with the finding that H-7 blocks pulmonary edema produced by hydrogen peroxide,'9 suggests that activation of protein kinase C may mediate increases in permeability during inflammation.
